🇺🇸 FDA
Pipeline program

zigakibart

CFUB523A12201

Phase 2 mab active

Quick answer

zigakibart for Immunoglobulin A Nephropathy (IgAN) is a Phase 2 program (mab) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Pharmaceuticals
Indication
Immunoglobulin A Nephropathy (IgAN)
Phase
Phase 2
Modality
mab
Status
active

Clinical trials